newsfilter
← Earnings
Earnings Releases·

ImageneBio — Third Quarter 2026 Earnings Summary

ImageneBio reported a net loss of $15.6 million for the third quarter of 2026, a decrease from the $24.8 million loss in the same period of 2025. The company ended the quarter with $126.6 million in cash and marketable securities, which is expected to fund operations through the first quarter of 2028. Clinical progress includes the ongoing Phase 2b ADAPTIVE trial for atopic dermatitis, with topline data anticipated in late 2027, and a Phase 2 study for alopecia areata scheduled to begin by the end of 2026. No cases of Kaposi sarcoma have been observed across all clinical trials to date.

Company
IMAGENEBIO INC
Sector
Healthcare
Industry
Biotechnology